Myotonic Dystrophy Type 1 (DM1) Most Likely Explains This Multisystem Presentation
This 29‑year‑old male with childhood‑onset myositis followed by progressive multisystem deterioration—including persistent hypotonia, muscle weakness, failure to gain weight despite polyphagia, cold intolerance, recurrent infections, ophthalmologic disturbances, cardiac arrhythmia, suppressed TSH with normal free T4, hypercalcemia, low aldosterone, and polyuria with low osmolality—most likely has myotonic dystrophy type 1 (DM1), which should be confirmed by DMPK gene CTG repeat expansion testing.
Rationale for DM1 as the Unifying Diagnosis
Multisystem Pattern Matches DM1
DM1 is characterized by progressive muscle weakness, hypotonia, and multisystem involvement affecting endocrine, cardiac, ophthalmologic, gastrointestinal, and immune systems 1, 2, 3.
The childhood onset following acute myositis could represent an initial inflammatory trigger in a patient with underlying DM1, as the disease shows extreme clinical variability with onset ranging from congenital to late adult life 1.
Muscle weakness with hypotonia and inability to gain weight despite increased appetite are classic features of DM1, where progressive muscle wasting occurs despite normal or increased caloric intake 1.
Endocrine Abnormalities Fit DM1
Suppressed TSH (0.022 mUI/L) with normal FT4 (1.9 ng/dL) represents subclinical hyperthyroidism, which can occur in DM1 patients who frequently develop thyroid dysfunction 1, 3.
Elevated testosterone (10.20 µg/L) with normal FSH/LH is paradoxical but can occur in DM1. While hypogonadism is more typical (affecting 40.8% of Chinese DM1 patients), endocrine abnormalities in DM1 show diverse manifestations 2.
Low aldosterone (dropped from 21.4 to 9.8 ng/dL) with low 17‑OHCS (7.28 µmol/24H) suggests partial adrenal insufficiency. While complete adrenal insufficiency is uncommon in DM1, adrenal involvement can occur as part of the multisystem endocrine dysfunction 1.
Hypercalcemia (2.57 mmol/L) with normal PTH (35.7 ng/L) may reflect altered calcium metabolism related to muscle breakdown or endocrine dysregulation in DM1 2.
Cardiac and Ophthalmologic Features
Arrhythmia is a cardinal feature of DM1, with cardiac conduction abnormalities occurring in 34.5% of patients and representing a major cause of morbidity 2, 3.
Ophthalmologic issues (focusing difficulties, dizziness while reading) are consistent with cataracts, which occur in 44.1% of DM1 patients and correlate independently with age 2.
Polyuria, Polydipsia, and Low Osmolality
Polyuria (2700 mL/24H) with low serum osmolality (279 mOsmol/kg) and excessive thirst could represent diabetes insipidus or inappropriate ADH secretion, both of which can occur with hypothalamic-pituitary dysfunction in multisystem disorders 1.
The normal fasting glucose (95 mg/dL) argues against diabetes mellitus, though insulin insensitivity can develop in DM1 due to altered splicing of insulin receptor genes 1.
Recurrent Infections and Immune Dysfunction
Frequent gastroenteritis, otitis, and signs of low pathogen resistance with mild leukopenia (4.3% leukocytes) and neutropenia (1.9% neutrophils) suggest immune dysfunction, which can occur in DM1 as part of multisystem involvement 2.
The neutrophil/lymphocyte ratio of 1.06 is low, indicating relative lymphocytosis or absolute neutropenia, potentially contributing to infection susceptibility.
Diagnostic Approach
Confirm DM1 with Genetic Testing
Measure CTG repeat expansion in the DMPK gene as the definitive diagnostic test. CTG repeats of 50–100 indicate mild disease, 100–1000 indicate classic disease, and >1000 indicate congenital disease 1.
The clinical presentation suggests classic adult‑onset DM1 (100–1000 CTG repeats) given the progressive multisystem involvement starting after childhood 1, 3.
Evaluate for Complications
Perform electrocardiogram and 24‑hour Holter monitoring to assess for conduction abnormalities, as cardiac involvement is a major predictor of mortality in DM1 and correlates with disease severity (MIRS score) 2.
Ophthalmologic examination with slit‑lamp to document cataracts, which are present in nearly half of DM1 patients and correlate with age 2.
Pulmonary function testing to assess for respiratory muscle weakness, though diaphragmatic involvement is less prominent in DM1 than in Pompe disease 1.
Endocrine panel including morning cortisol, ACTH stimulation test, and thyroid function to fully characterize the extent of endocrine dysfunction 1, 2.
Rule Out Alternative Diagnoses
Pompe disease (GSD II) was considered given childhood hypotonia and muscle weakness, but the absence of cardiomegaly, hepatomegaly, and respiratory distress argues against infantile Pompe, while the multisystem endocrine and cardiac features are atypical for late‑onset Pompe 1.
Primary adrenal insufficiency could explain low aldosterone and 17‑OHCS, but the normal 10 AM cortisol (14.3 µg/dL) and ACTH (16.4 ng/L) make complete adrenal failure unlikely 1.
Inflammatory myopathies (polymyositis/dermatomyositis) were considered given the initial myositis, but the chronic progressive course, multisystem involvement, and absence of elevated CK or inflammatory markers make this less likely 1, 4.
Histiocytic disorders (Erdheim‑Chester disease) can cause multisystem involvement with endocrine dysfunction, but the muscle‑predominant presentation and absence of bone pain or characteristic imaging findings make this unlikely 1.
Management Strategy
Supportive and Symptomatic Treatment
No disease‑modifying therapies are currently available for DM1, so management focuses on surveillance, preventative measures, and supportive treatments 3.
Treat cardiac arrhythmias with antiarrhythmic medications or pacemaker placement as indicated by cardiology evaluation 2, 3.
Address endocrine abnormalities: Consider levothyroxine if subclinical hyperthyroidism progresses to hypothyroidism; monitor for adrenal insufficiency and consider hydrocortisone replacement if symptoms worsen or stress dosing is needed 1, 2.
Manage polyuria/polydipsia: If diabetes insipidus is confirmed with water deprivation testing, treat with desmopressin 1.
Nutritional support with high‑calorie, high‑protein diet to address failure to gain weight despite polyphagia 1.
Multidisciplinary Monitoring
Regular cardiac monitoring with annual ECG and echocardiography, as cardiac conduction abnormalities are a major cause of sudden death in DM1 2, 3.
Annual ophthalmologic examination for cataract progression, which may require surgical intervention 2.
Pulmonary function testing every 1–2 years to monitor for respiratory muscle weakness 3.
Endocrine surveillance with annual thyroid function, testosterone, and cortisol testing to detect progressive dysfunction 2.
Genetic Counseling
DM1 is autosomal dominant with anticipation, meaning offspring have a 50% risk of inheritance with potential for earlier onset and greater severity 1.
Maternal transmission carries higher risk of congenital DM1 with severe neonatal hypotonia and respiratory distress 1.
Critical Pitfalls to Avoid
Do not delay genetic testing while pursuing extensive endocrine or rheumatologic workup, as DM1 genetic testing is definitive and will guide all subsequent management 1.
Do not attribute all symptoms to a single endocrine disorder (e.g., thyroid dysfunction alone), as this will miss the underlying multisystem genetic disease 2, 3.
Do not overlook cardiac monitoring, as sudden cardiac death from conduction abnormalities is a leading cause of mortality in DM1 and requires proactive management 2, 3.
Do not assume stable disease, as DM1 is progressive with somatic mosaicism causing continuous CTG repeat expansion throughout life, leading to worsening symptoms over time 1.